Apricus Biosciences Inc: (NASD: APRI)

$2.51

-0.06 (-2.34%)

Volume 327,860

Jun 19 04:00 PM ET

Zacks Rank: 3-Hold

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		2.50 - 2.59
	
		52wk Low - High
		1.89 - 3.63
	
		Previous Close
		2.57
	
		Avg. Volume
		1,081,402
	
		Industry
		MED-DRUGS
	
		Market Cap
		93.43 M
	
		Div - Yield
		0.00 - 0.00
	
		Beta
		1.83
	
		P/E (F1)
		0.00
	
		Current Year Est.
		-0.58
	
		Quarterly Earnings ESP 
		NA
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		4
Sell

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Neutral
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		112 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 06/14/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            P/E (F1)
                            NA
                        
                            PEG Ratio
                            NA
                        
                            Current Year Est.
                            -0.58
                        
                            Current Quarter Estimate
                            -0.13
                        
                            Most Accurate Estimate
                            NA
                        
                            Earnings ESP 
                            NA
                        
                            Next Earnings Report Date
                            08-09-2013
                        
                            EPS Last Year
                            -0.78
                        
                            Expected Earnings Growth
                            NA
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
Apricus Bio operates in the pharmaceutical industry and focuses on research and development in the area of drug delivery. Its proprietary drug delivery technology is called NexACT ?. Backed by revenue generating CRO business, Bio-Quant, Inc. and its NexMed USA subsidiary, Apricus Bio has leveraged the flexibility of its proven NexACT? drug delivery technology to enable multi-route administration of new and improved compounds across numerous therapeutic classes. The Company is seeking to monetize its existing product pipeline, including compounds from pre-clinical through Phase 3, currently focused on dermatology, sexual dysfunction and cancer. Apricus Bio was formerly known as NexMed, Inc and is headquartered in San Diago, California.   
Full APRI Company Report

 Snapshot on APRI

NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
APRI Chart  by YCharts

Earnings Estimates

	Current Qtr (06/2013)	Next Qtr (09/2013)	Current Year (12/2013)	Next Year (12/2014)
Average Estimate	-0.13	-0.09	-0.58	-0.40
Number of Estimates	1	1	2	1
Low Estimate	-0.13	-0.09	-0.60	-0.40
High Estimate	-0.13	-0.09	-0.55	NA
Year Ago EPS	NA	NA	-0.58	-0.58
EPS Growth	NA	NA	0.86%	30.43%

More APRI Estimates

Average Earnings Estimates for APRI

EPS Growth for APRI

Industry Analysis

Name	Symbol	Previous Close
APPRICUS BIOSCI	APRI	2.57
JAZZ PHARMACEUT	JAZZ	69.66
SALIX PHARM-LTD	SLXP	66.83
SANTARUS INC	SNTS	22.28
USANA HLTH SCI	USNA	74.58
ARADIGM CORP	ARDM	0.17
CELL THERAPEUT	CTIC	1.33
DURECT CORP	DRRX	0.83
ELAN CP PLC ADR	ELN	13.78
FLAMEL TECH	FLML	6.16

Sector:Medical>> Industry:MED-DRUGS

COMPARE TICKER vs. Its Peers

Zacks Commentary

Apricus' Vitaros Approved in Europe

Jun 11, 2013

Apricus Offloads Non-Core Assets

Apr 04, 2013

Apricus, Takeda Ink Marketing Deal

Sep 14, 2012

Report for APRI

Jun 14, 2013

More APRI Zacks Commentary

Financials

EPS TTM	-0.78
Sales	8
Net Income	-19
Price/Earnings	NA
Price/Book	11.61
Price/Cash Flow	NA
Price/Sales	28.36

More APRI Financials

News

New Research Grants, Product Launches, and Positive Clinical Study Results - Research Report on Boston Scientific, Cooper, Arena Pharmaceuticals, Apricus Biosciences, and NewLink Genetics - Pr Newswire

Jun 13, 2013

Apricus Wins EU Approval for Vitaros for ED - Benzinga

Jun 10, 2013

CEO and CFO Buys Weekly Update - GuruFocus

May 29, 2013

Apricus Bio to Float New Stock and Warrants - TheMotleyFool

May 24, 2013

Apricus Biosciences Inc expects USD17.1m in public offering - M2

May 24, 2013

Apricus Biosciences Inc plans to launch public offering - M2

May 23, 2013

Apricus Biosciences Prices $17.1 Million Public Offering of Common Stock and Warrants - Globenewswire

May 23, 2013

Apricus Biosciences prices $17.1 million public offering of common stock - Datamonitor Financial Deals Tracker

May 23, 2013

See All News Stories on APRI

Broker Recommendations

Current ABR	1.00
ABR (Last Week)	1.00
# of recs in ABR	3
Average Target Price	5.81
Industry Rank by ABR	112 out of 265
Rank in Industry	81 out of 95

More APRI Broker Recommendations

Username: Password:

Remember me [?]

Forgot Password

New Member

Apricus Biosciences Inc: (NASD: APRI)

$2.51

-0.06 (-2.34%)

Volume 327,860

Jun 19 04:00 PM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks #1 Rank Strong Buys

Zacks Recommendation Long-Term: 6+ Months

All Outperform Rated Stocks

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description

Earnings Estimates

Industry Analysis

Sector:Medical>> Industry:MED-DRUGS

Zacks Commentary

Apricus' Vitaros Approved in Europe

Apricus Offloads Non-Core Assets

Apricus, Takeda Ink Marketing Deal

Report for APRI

Financials

News

New Research Grants, Product Launches, and Positive Clinical Study Results - Research Report on Boston Scientific, Cooper, Arena Pharmaceuticals, Apricus Biosciences, and NewLink Genetics - Pr Newswire

Apricus Wins EU Approval for Vitaros for ED - Benzinga

CEO and CFO Buys Weekly Update - GuruFocus

Apricus Bio to Float New Stock and Warrants - TheMotleyFool

Apricus Biosciences Inc expects USD17.1m in public offering - M2

Apricus Biosciences Inc plans to launch public offering - M2

Apricus Biosciences Prices $17.1 Million Public Offering of Common Stock and Warrants - Globenewswire

Apricus Biosciences prices $17.1 million public offering of common stock - Datamonitor Financial Deals Tracker

Broker Recommendations

Day Low - High	2.50 - 2.59
52wk Low - High	1.89 - 3.63
Previous Close	2.57
Avg. Volume	1,081,402
Industry	MED-DRUGS
Market Cap	93.43 M
Div - Yield	0.00 - 0.00
Beta	1.83
P/E (F1)	0.00
Current Year Est.	-0.58
Quarterly Earnings ESP	NA

P/E (F1)	NA
PEG Ratio	NA
Current Year Est.	-0.58
Current Quarter Estimate	-0.13
Most Accurate Estimate	NA
Earnings ESP	NA
Next Earnings Report Date	08-09-2013
EPS Last Year	-0.78
Expected Earnings Growth	NA